Intuitive Surgical, Inc. (ISRG) Stock Price & How to Invest

Intuitive Surgical (ISRG) is the dominant maker of robotic-assisted surgery systems, best known for the da Vinci platform used in minimally invasive procedures across urology, gynecology, general surgery, and other specialties. Its business model is razor-and-blade: Intuitive sells or places the large capital systems, then earns high-margin recurring revenue from the single-use instruments and accessories consumed in each procedure, plus service contracts. As the installed base of systems grows and procedure volumes rise, recurring revenue compounds. The company has expanded its platform with newer systems (including the da Vinci 5 and the Ion platform for lung biopsy), and benefits from surgeon training, hospital workflow integration, and a large library of validated procedures that create high switching costs. Intuitive went public in 2000 and is headquartered in Sunnyvale, California. It is the clear leader in surgical robotics with a wide moat, strong margins, and consistent procedure-volume growth, though it trades at a premium valuation that reflects those qualities.

ISRG trades at a premium valuation, so any slowdown in procedure growth, system placements, or margins can compress the multiple sharply. Competition is intensifying as Medtronic, Johnson & Johnson, and others develop rival surgical-robotics platforms that could erode Intuitive's dominance over time. Hospital capital budgets are cyclical and can defer system purchases in tight economic periods. Reimbursement changes, regulatory scrutiny of new systems, and any safety or recall issues are risks. The company is also exposed to global healthcare-spending trends and currency, and the high valuation leaves little room for execution missteps.

29 analysts publish price targets on ISRG, averaging $477.25 against a $353.33 price as of August 2026, or +35.1%. The published targets run from $324.00 to $685.00, a wide spread, and the ratings split 23 buy, 9 hold, 1 sell. Over the last six months there have been 0 raises and 11 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ISRG forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Intuitive Surgical, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Razor-and-blade recurring revenue. Intuitive earns the majority of revenue from the single-use instruments, accessories, and service contracts consumed every time a da Vinci procedure runs, not just from selling systems. The most optimistic published target, $685.00, assumes this works close to its best case.

The case against. ISRG trades at a premium valuation, so any slowdown in procedure growth, system placements, or margins can compress the multiple sharply. The most pessimistic target, $324.00, is roughly what ISRG is worth if this bites instead.

Read the full bull and bear case on ISRG, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Intuitive Surgical, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$8 to 9 billion (verify)
• Recurring revenue share: ~80%+ from instruments, accessories, and service
• Operating margin: ~30% (strong)
• Gross margin: ~65% to 68%
• P/E (TTM): ~60x to 75x (premium; verify)
• Dividend: Initiated a modest dividend recently (verify status and yield)
• Procedure growth: High-single to low-double-digit annual growth
• Balance sheet: Strong; large net cash position

Intuitive trades at a high earnings multiple that reflects its dominant market position, high-margin recurring revenue, strong balance sheet, and consistent procedure-volume growth. The premium is the central debate: bulls justify it with the durability of the razor-and-blade model and a long runway, while bears point to multiple-compression risk if procedure growth slows or competitors gain share. Figures are approximate and should be verified against the latest filing.

If you want ISRG exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

These are the investment theses ISRG naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that sit close to ISRG: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ISRG exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (BOTZ, ROBO, XLV), which spreads the position across many companies. Or build it into a focused thematic portfolio, so ISRG sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ISRG fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Intuitive Surgical (ISRG) is a wide-moat medtech compounder whose recurring instrument and service revenue grows with procedure volume on a large installed base. In a portfolio it behaves as a high-quality healthcare growth holding with strong margins and durable demand, balanced by a premium valuation, which is how most long-term holders frame it.

Whether ISRG is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ISRG a buy or a sell?, and where the stock could go from here in the ISRG stock forecast.

For income investors, whether ISRG pays a dividend and how the payout looks is covered in does ISRG pay a dividend? And to weigh ISRG against a peer, read the full side-by-side comparisons: ISRG vs ABB and ISRG vs ROK.